numares Initiates Worldwide Commercial Launch of insightLP™-S50 to Provide New Insights in Lipoprotein Research

REGENSBURG, Germany, Feb. 07, 2017 -- Fast-growing commercial-stage diagnostics company numares AG today announced the worldwide launch of its new, software-based test insightLP™-S50, part of the Company’s lipoFIT^® series for lipoprotein profiling. insightLP-S50 enables research groups worldwide to analyze lipoprotein composition in detail, thus creating new possibilities in lipid analytics. The test can help clarify how the lipoprotein composition affects the risk of diabetes or cardiovascular disease and determine the effects of individual nutritional habits on lipoprotein composition.

numares is an established developer and supplier of innovative high-throughput testing methods for medical diagnostics and biomedical research with expertise in the nuclear magnetic resonance (NMR) spectroscopic analysis of lipoproteins. Lipoproteins transport cholesterol and lipids throughout the body and have been involved in the development of arteriosclerosis and other cardiovascular diseases. Although it is assumed that the composition of individual lipoproteins may play a decisive role, this cannot be detected using the routine diagnostics available until now.

The insightLP-S50 test analyzes lipoprotein particles in detail and determines their respective quantity of the key compounds triglycerides, cholesterol and phospholipids. The insightLP-S50 measures a total of 41 parameters. ”By using our new test of the lipoFIT series, research can gain further important insights into the role of certain lipoprotein particles, particularly in the development of atherosclerosis“, says Dr. Titus Kaletta, member of the executive board of numares AG and chief operating officer responsible for the commercialization of the lipoFIT series. “The insightLP-S50 test allows researchers to look into lipoprotein particles and investigate whether and to what extent their structure correlates with an increased risk of a disease.”

The test principle of insightLP-S50 is based on the evaluation of standardized NMR spectra that derive from serum samples when using numares’ software-based AXINON^® system. The AXINON system allows two already established in vitro diagnostic (IVD) tests to be used for the advanced analysis of lipoproteins. In 2015, numares launched two lipid tests, lipoFIT-S100 and lipoFIT-S100-400, which measure lipoprotein particle concentration, size and cholesterol for the assessment of cardiovascular risk. Since then, more than 1 million tests have been performed in the U.S. using numares’ technology. In Europe, this advanced lipid analysis is offered as IVD in cooperation with the German laboratory chain Limbach Group and under the brand name LipoComplete.

“The worldwide commercialization of insightLP-S50 is a further important step for boosting lipoprotein research and gaining new insights into diseases and processes in the human body,” explains Dr. Maximilian Zucker, member of the executive board of numares AG and head of R&D at numares. “All tests of the lipoFIT series guarantee the highest data quality and comparability for researchers worldwide thanks to the in-process quality assurance of the AXINON test system. This also allows for the unlimited reprocessing of data with further numares tests, focusing on new aspects each time. This is a great advancement in lipoprotein research.”

About numares
numares AG is a fast-growing innovative diagnostics company that develops and markets software-based test systems for high-throughput use in clinical diagnostics and life science research. The AXINON^® IVD system and its diagnostic tests employ nuclear magnetic resonance (NMR) spectroscopy creating a numeric spectrum with which to evaluate metabolomic networks. The output of these analyses provide physicians with valuable information on the disease status of patients. numares developed its proprietary Magnetic Group Signaling^® (MGS^®) technology to enable NMR for highly standardized and rapid throughput testing, making it a cost-efficient new solution for diagnostic purposes. The metabolomics tests address unmet medical needs in the indication fields of cardiovascular diseases, nephrology, oncology and neurology, shaping another important pillar in precision medicine.

You will find more information at www.numares.com.

For further information please contact:
numares AG
Dipl.-Biol. Christiane Proll, MBA
Tel.: +49 941 2809 49-14
E-Mail: [email protected]

IRA WÜLFING KOMMUNIKATION GmbH
Dr. Reinhard Saller
Tel.: +49 89 2000 30-30
E-Mail: [email protected]

U.S.A.
The Ruth Group
Investors:
Robert Flamm, Ph.D.
Tel.: 1-646-536-7017
E-Mail: [email protected]

Media: 
Kirsten Thomas
Tel: 1-508-280-6592
E-Mail: [email protected]